Editor of Business Today wrote "All Eyes On Genting’s TauRx Alzheimer Phase 3 Trial" on 5 March.

On 7 Mar 2024, Genting Berhad’s 20%-owned TauRx will present full results from its Phase 3 LUCIDITY trial of HMTM that is designed to combat Alzheimer’s disease. It has initiated regulatory engagement in the United Kingdom and the United States for product approval.

Under a ‘blue sky’ scenario where HMTM is approved and TauRx is valued at USD15b with no discount ascribed to it, Maybank IB says GENT TP could be raised to MYR9.40. As for now the house estimates MYR5.73 TP unchanged but encourages investors to BUY now to position ahead.


BUT how do we interpret the ACTUAL RESULTS announced over the weekend?


Taurx announcement on drug trial results 2024
Experimental pill on sale in HK for China market?